Eli Lilly And Company
$1.09T- Market cap
- $1.06T
- Debt
- +$42.50B
- Cash
- −$7.27B
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $1.06T · View financials
Snapshot Sep 10, 2026, 4:00 PM ET
FY 2025 · Mkt cap
Decision snapshot: LLY stock price at premium vs NVAX $1.12K current versus $82.73 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NVAX's multiple
Implied fair value · at LLY's multiple
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Higher P/E
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Capital structure 96% equity / 4% debt · EV / Revenue 16.76x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ELI LILLY AND COMPANY · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
NOVAVAX INC · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
LLY vs PFE
Merck & Co., Inc.
LLY vs MRK
Johnson & Johnson
LLY vs JNJ
AbbVie Inc.
LLY vs ABBV
Amgen Inc.
LLY vs AMGN
Bristol-Myers Squibb Company
LLY vs BMY
Moderna, Inc.
LLY vs MRNA
BioNTech SE
LLY vs BNTX
Emergent BioSolutions Inc.
LLY vs EBS
ASTRAZENECA PLC
LLY vs AZN
GSK plc
LLY vs GSK
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe LLY can sustain its premium through continued 40%+ revenue growth and very high margins, then hold or selectively own it because the stock is still inside its historical band and supported by strong profitability; otherwise, NVAX and DCF comparisons argue for caution because the current price is far above both reference valuations.
LLY’s current price of $1148.84 is far above NVAX-implied price range of $47.21 to $74.15 and also above the DCF range of $223.55 to $302.46, indicating a very large valuation gap. The stock is still within its historical band of $1033.96 to $1263.72, so the market is implicitly leaning on franchise quality and future earnings power rather than near-term relative valuation.
Supporting Metrics